Facebook
Twitterhttps://media.market.us/privacy-policyhttps://media.market.us/privacy-policy
(Source: WHO, American Cancer Society)
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
This dataset of breast cancer patients was obtained from the 2017 November update of the SEER Program of the NCI, which provides information on population-based cancer statistics. The dataset involved female patients with infiltrating duct and lobular carcinoma breast cancer (SEER primary cites recode NOS histology codes 8522/3) diagnosed in 2006-2010. Patients with unknown tumour size, examined regional LNs, positive regional LNs, and patients whose survival months were less than 1 month were excluded; thus, 4024 patients were ultimately included.
Facebook
TwitterWorldwide, breast cancer is the most common type of cancer in women and the second highest in terms of mortality rates.Diagnosis of breast cancer is performed when an abnormal lump is found (from self-examination or x-ray) or a tiny speck of calcium is seen (on an x-ray). After a suspicious lump is found, the doctor will conduct a diagnosis to determine whether it is cancerous and, if so, whether it has spread to other parts of the body.
This breast cancer dataset was obtained from the University of Wisconsin Hospitals, Madison from Dr. William H. Wolberg.
Facebook
TwitterDeath rate has been age-adjusted to the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Obesity can increase an individual’s lifetime risk of breast cancer. Promoting healthy food retail and physical activity and improving access to preventive care services are important measures that cities and communities can take to prevent breast cancer.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.
Facebook
TwitterIn 2022, 175 females per 100,000 population were registered in England as newly diagnosed with breast cancer. This was an overall increase in comparison to the last few years' rate of registration. This statistic shows the rate of newly diagnosed female cases of breast cancer per 100,000 population in England from 1995 to 2022.
Facebook
TwitterThe population of Middle Tennessee was assessed using publically available data collected in 2009 describing demographic and breast cancer-related characteristics of the population.*The value for each breast cancer risk factor was determined for each Middle Tennessee County, and counties were then ranked in numerical order from lowest to highest. The numerically ranked counties were then subdivided into quartiles, such that the three counties with the lowest risk factor values were placed in Quartile 1, and those with the highest were placed in Quartile 4. The range of risk factor values encompassed by each quartile are shown.1The percentage of the total female population in the county that is over the age of 50 years (a surrogate for menopause).2The breast cancer incidence per 100,000 women. 3Breast cancer mortality per 100,000 women.4The percentage of all breast cancers that were diagnosed at Stage IV.5The percentage of all breast cancers that were diagnosed without a prior mammographic screening.6The percentage of the female population lacking any form of health insurance.7The median household income.8The percentage of the population possessing higher than a high school level education.9The percentage of the population that is not Caucasian.
Facebook
TwitterIn 2022, there were around *** new cases of breast cancer per 100,000 population in the state of Connecticut, making it the state with the highest breast cancer incidence rate that year. This statistic shows the incidence rate of breast cancer in the U.S. in 2022, by state.
Facebook
Twitterhttps://digital.nhs.uk/about-nhs-digital/terms-and-conditionshttps://digital.nhs.uk/about-nhs-digital/terms-and-conditions
Mortality from breast cancer (ICD-10 C50 equivalent to ICD-9 174). To reduce deaths from breast cancer. Legacy unique identifier: P00154
Facebook
TwitterRate: Number of new cases of breast cancer (per 100,000) diagnosed at the regional or distant stage among females.
Definition: Age-adjusted incidence rate of invasive breast cancer per 100,000 female population.
Data Sources:
(1) NJ State Cancer Registry, Dec 31, 2015 Analytic File, using NCI SEER*Stat ver 8.2.1 (www.seer.cancer.gov/seerstat)
(2) NJ population estimates as calculated by the NCI's SEER Program, released January 2015, http://www.seer.cancer.gov/popdata/download.html.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
BackgroundThis nationwide study examined breast cancer (BC) incidence and mortality rates in Hungary between 2011–2019, and the impact of the Covid-19 pandemic on the incidence and mortality rates in 2020 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary.MethodsOur nationwide, retrospective study included patients who were newly diagnosed with breast cancer (International Codes of Diseases ICD)-10 C50) between Jan 1, 2011 and Dec 31, 2020. Age-standardized incidence and mortality rates (ASRs) were calculated using European Standard Populations (ESP).Results7,729 to 8,233 new breast cancer cases were recorded in the NHIF database annually, and 3,550 to 4,909 all-cause deaths occurred within BC population per year during 2011-2019 period, while 2,096 to 2,223 breast cancer cause-specific death was recorded (CSO). Age-standardized incidence rates varied between 116.73 and 106.16/100,000 PYs, showing a mean annual change of -0.7% (95% CI: -1.21%–0.16%) and a total change of -5.41% (95% CI: -9.24 to -1.32). Age-standardized mortality rates varied between 26.65–24.97/100,000 PYs (mean annual change: -0.58%; 95% CI: -1.31–0.27%; p=0.101; total change: -5.98%; 95% CI: -13.36–2.66). Age-specific incidence rates significantly decreased between 2011 and 2019 in women aged 50–59, 60–69, 80–89, and ≥90 years (-8.22%, -14.28%, -9.14%, and -36.22%, respectively), while it increased in young females by 30.02% (95%CI 17,01%- 51,97%) during the same period. From 2019 to 2020 (in first COVID-19 pandemic year), breast cancer incidence nominally decreased by 12% (incidence rate ratio [RR]: 0.88; 95% CI: 0.69–1.13; 2020 vs. 2019), all-cause mortality nominally increased by 6% (RR: 1.06; 95% CI: 0.79–1.43) among breast cancer patients, and cause-specific mortality did not change (RR: 1.00; 95%CI: 0.86–1.15).ConclusionThe incidence of breast cancer significantly decreased in older age groups (≥50 years), oppositely increased among young females between 2011 and 2019, while cause-specific mortality in breast cancer patients showed a non-significant decrease. In 2020, the Covid-19 pandemic resulted in a nominal, but not statistically significant, 12% decrease in breast cancer incidence, with no significant increase in cause-specific breast cancer mortality observed during 2020.
Facebook
TwitterMIT Licensehttps://opensource.org/licenses/MIT
License information was derived automatically
This dataset contains Cancer Incidence data for Breast Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for females segmented by age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.
Facebook
Twitterhttps://dataful.in/terms-and-conditionshttps://dataful.in/terms-and-conditions
This dataset provides estimated mortality figures for cervical and breast cancer in India, which affect women nationwide, based on the National Cancer Registry Programme's report.
Facebook
TwitterIn 2022, the mortality rate of breast cancer in women in Europe was **** per 100,000 women. Cyprus had the highest mortality rate at **** per 100,000, followed by Slovakia with **** per 100,000 women. Conversely, Spain had the lowest mortality rate at **** per 100,000. This statistic depicts the mortality rate of breast cancer in Europe in 2022 in women population, by country.
Facebook
TwitterOpen Government Licence 3.0http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/
License information was derived automatically
Deaths from breast cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data
Facebook
Twitterhttps://digital.nhs.uk/about-nhs-digital/terms-and-conditionshttps://digital.nhs.uk/about-nhs-digital/terms-and-conditions
Legacy unique identifier: P00148
Facebook
TwitterBackground Increased BRCA1 and BRCA2 germline mutation rates have been reported in Ashkenazi Jewish women in North America, Europe and Israel, and have been mentioned as possibly related to a higher incidence of breast and ovarian cancer among these communities. The present study was carried out with the aim of obtaining evidence on the magnitude of breast cancer as a cause of death among Ashkenazi women in Brazil.
Methods
We reviewed all death certificates archived in the Jewish Burial Societies of São Paulo (1971-1997) and Porto Alegre (1948-1997), two of the main and oldest Jewish communities in Brazil. Breast cancer observed deaths were compared with expected deaths according to breast cancer mortality in the general population.
Results
The observed ratios were approximately quite close to unity, suggesting a similar breast cancer mortality pattern among the Ashkenazi population and the general population in both cities. These results maintain similar behavior regardless of whether analyzed before or after the mid-1980s, when mammography came to be increasingly performed in Brazil. Cancer proportional mortality ratios were 1.04 (0.83-1.29) in São Paulo and 1.16 (0.84-1.57) in Porto Alegre before 1985, and 1.17 (1.00-1.44) and 1.21 (0.81-1.79), respectively, between 1985 and 1997. Some evidence of the maintenance of protective risk factors such as high parity has been observed among Ashkenazi women in São Paulo.
Conclusion
A quite similar breast cancer mortality pattern was observed between Ashkenazi Jewish women and the general population in São Paulo and Porto Alegre, Brazil. These results may suggest an environmental role on germ mutation expression reported in this ethnic group.
Facebook
Twitterhttps://dataful.in/terms-and-conditionshttps://dataful.in/terms-and-conditions
The dataset consists of the state wise estimated incidence of breast cancer and cervical cancer in India as per the National Cancer Registry Programme. The estimates are computer using age specific incidence Rate of 28 PBCRs of 2012-2016 and the projected population (person-years). NB: Incidence estimates of breast cancer is available since 2016 while that of cervical cancer is available since 2015.
Facebook
Twitterhttps://creativecommons.org/publicdomain/zero/1.0/https://creativecommons.org/publicdomain/zero/1.0/
This dataset was created by Maham9
Released under CC0: Public Domain
Facebook
Twitterhttps://creativecommons.org/publicdomain/zero/1.0/https://creativecommons.org/publicdomain/zero/1.0/
Breast cancer is the most frequently diagnosed cancer and the most frequent cause for cancer-related deaths in women worldwide. Globally, breast cancer accounted for 2.08 million out of 18.08 million new cancer cases (incidence rate of 11.6%) and 626,679 out of 9.55 million cancer-related deaths (6.6% of all cancer-related deaths) in 2018. 1,2 In India, breast cancer has surpassed cancers of the cervix and the oral cavity to be the most common cancer and the leading cause of cancer deaths. In 2018, 159,500 new cases of breast cancer were diagnosed, representing 27.7% of all new cancers among Indian women and 11.1% of all cancer deaths.
In india breast cancer cases reporting and diagnotics have increased 10 times in past 3 years . All thanks to the various cancer awareness initiatives by both private and govt. organisations.
Facebook
Twitterhttps://media.market.us/privacy-policyhttps://media.market.us/privacy-policy
(Source: WHO, American Cancer Society)